Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Sep;30(3):471–475. doi: 10.1111/j.1365-2125.1990.tb03799.x

Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.

H H Zhou 1, L B Anthony 1, A J Wood 1, G R Wilkinson 1
PMCID: PMC1368151  PMID: 2223426

Abstract

Studies were performed in 13 healthy subjects to determine whether treatment with rifampicin results in induction of the metabolism of mephenytoin. Daily dosing with 600 mg rifampicin for 22 days caused a three to eightfold increase in the 0-8 h urinary R/S ratio of mephenytoin following oral administration (100 mg) of racemic drug to extensive metabolizers of the anticonvulsant. This was accompanied by a 40 to 180% increase in the 0-8 h urinary excretion of the 4'-hydroxy metabolite. Four weeks after discontinuing rifampicin, both metabolic indices had returned to their baseline values. By contrast, rifampicin had no effect on either measures of metabolism in subjects of the poor metabolizer phenotype. Thus, it appears that the activity of the enzyme (P-450 MP) mediating the genetically determined 4'-hydroxylation of S-mephenytoin can be significantly modulated by enzyme inducing agents such as rifampicin and possibly environmental agents with a similar ability.

Full text

PDF
471

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atiba J. O., Blaschke T. F., Wilkinson G. R. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. Br J Clin Pharmacol. 1989 Aug;28(2):161–165. doi: 10.1111/j.1365-2125.1989.tb05409.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baciewicz A. M., Self T. H. Rifampin drug interactions. Arch Intern Med. 1984 Aug;144(8):1667–1671. doi: 10.1001/archinte.144.8.1667. [DOI] [PubMed] [Google Scholar]
  3. Branch R. A., Herman R. J. Enzyme induction and beta-adrenergic receptor blocking drugs. Br J Clin Pharmacol. 1984;17 (Suppl 1):77S–84S. doi: 10.1111/j.1365-2125.1984.tb02432.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chandler M. H., Scott S. R., Blouin R. A. Age-associated stereoselective alterations in hexobarbital metabolism. Clin Pharmacol Ther. 1988 Apr;43(4):436–441. doi: 10.1038/clpt.1988.55. [DOI] [PubMed] [Google Scholar]
  5. Eichelbaum M., Gross A. S. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. Pharmacol Ther. 1990;46(3):377–394. doi: 10.1016/0163-7258(90)90025-w. [DOI] [PubMed] [Google Scholar]
  6. Eichelbaum M., Mineshita S., Ohnhaus E. E., Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol. 1986 Jul;22(1):49–53. doi: 10.1111/j.1365-2125.1986.tb02879.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Funck-Brentano C., Kroemer H. K., Pavlou H., Woosley R. L., Roden D. M. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol. 1989 Apr;27(4):435–444. doi: 10.1111/j.1365-2125.1989.tb05391.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Funck-Brentano C., Turgeon J., Woosley R. L., Roden D. M. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther. 1989 Apr;249(1):134–142. [PubMed] [Google Scholar]
  9. Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacol Rev. 1988 Dec;40(4):243–288. [PubMed] [Google Scholar]
  10. Heinemeyer G., Gramm H. J., Simgen W., Dennhardt R., Roots I. Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital. Eur J Clin Pharmacol. 1987;32(3):273–277. doi: 10.1007/BF00607575. [DOI] [PubMed] [Google Scholar]
  11. Jacqz E., Hall S. D., Branch R. A., Wilkinson G. R. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther. 1986 Jun;39(6):646–653. doi: 10.1038/clpt.1986.113. [DOI] [PubMed] [Google Scholar]
  12. James R., Küpfer A., Villeneuve J. P., Branch R. A. Induction of drug-metabolizing enzymes by the enantiomers of normephenytoin in the rat. Drug Metab Dispos. 1981 May-Jun;9(3):297–302. [PubMed] [Google Scholar]
  13. Knodell R. G., Dubey R. K., Wilkinson G. R., Guengerich F. P. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther. 1988 Jun;245(3):845–849. [PubMed] [Google Scholar]
  14. Küpfer A., Roberts R. K., Schenker S., Branch R. A. Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther. 1981 Jul;218(1):193–199. [PubMed] [Google Scholar]
  15. Leemann T., Dayer P., Meyer U. A. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol. 1986;29(6):739–741. doi: 10.1007/BF00615971. [DOI] [PubMed] [Google Scholar]
  16. Schellens J. H., van der Wart J. H., Brugman M., Breimer D. D. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther. 1989 May;249(2):638–645. [PubMed] [Google Scholar]
  17. Shaheen O., Biollaz J., Koshakji R. P., Wilkinson G. R., Wood A. J. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. Clin Pharmacol Ther. 1989 Apr;45(4):439–443. doi: 10.1038/clpt.1989.52. [DOI] [PubMed] [Google Scholar]
  18. Vesell E. S. Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):659–679. doi: 10.1002/cpt1977225part2659. [DOI] [PubMed] [Google Scholar]
  19. Wedlund P. J., Aslanian W. S., Jacqz E., McAllister C. B., Branch R. A., Wilkinson G. R. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther. 1985 Sep;234(3):662–669. [PubMed] [Google Scholar]
  20. Wedlund P. J., Aslanian W. S., McAllister C. B., Wilkinson G. R., Branch R. A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984 Dec;36(6):773–780. doi: 10.1038/clpt.1984.256. [DOI] [PubMed] [Google Scholar]
  21. Wilkinson G. R., Guengerich F. P., Branch R. A. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther. 1989;43(1):53–76. doi: 10.1016/0163-7258(89)90047-8. [DOI] [PubMed] [Google Scholar]
  22. Zilly W., Breimer D. D., Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):219–227. doi: 10.1007/BF00614021. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES